Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study

Stock Information for Lexaria Bioscience Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Lexaria Bioscience Corp.

Lexaria Releases Strategic Letter from the Outgoing CEO
Lexaria Welcomes Industry Veteran as New CEO
Lexaria Enters a Material Transfer Agreement for DehydraTECH Research
Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus Oral Capsules
Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules
First Results from Lexaria's Second GLP-1 Human Pilot Study
Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study
Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.